In Vitro: Lansoprazole from 0.3 to 3 μM inhibits gastric acid formation in a concentration-dependent manner (IC50 of 0.76 μM).
Lansoprazole (30-300 μM) both induced concentration-dependent, reversible and reproducible relaxations of arteries.
In Vivo: Lansoprazole (20-40 mg/kg) treatment significantly attenuated STZ and HFD -induced memory deficits, biochemical and histopathological alterations.
Lansoprazole (20 mg/kg and 40 mg/kg, p.o.) significantly reduces the STZ and HFD- induced increase in AChE activity.
Lansoprazole (20 mg/kg and 40 mg/kg, p.o.) significantly reduces the STZ and HFD- induced rise in brain MPO level.
Further HFD mice treated with lansoprazole (20 mg/kg and 40 mg/kg, p.o.) shows a marked decrease in the body weight in comparison to the control animals.